loading...

COA Instruments Distributed by Mapi Research Trust

default distrib

I-PSS / International Prostate Symptom Score International Prostate Symptom Score

Barry MJ et al.

To capture the severity of urinary symptoms related to benign prostatic hyperplasia

Therapeutic indications : Benign Prostatic Hyperplasia

default distrib

I-TAQ / Injection Treatment Acceptance Questionnaire Injection Treatment Acceptance Questionnaire

Sanofi Aventis, Regeneron Pharmaceuticals Inc et al.

To assess treatment acceptance with a subcutaneous injection therapy for an asymptomatic condition

Therapeutic indications : All

default distrib

IBHQ © / Impact of Bronchiolitis Hospitalisation Questionnaire Impact of Bronchiolitis Hospitalisation Questionnaire

Abbott (France) et al.

To comprehensively assess the impact of bronchiolitis hospitalization on parents, both just after hospital discharge and three months after hospital discharge

Therapeutic indications : Bronchiolitis

default distrib

IBM-FRS / Inclusion Body Myositis - Functional Rating Scale Inclusion Body Myositis - Functional Rating Scale

Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L, The Muscle Study Group (MSG) et al.

To assess activities of daily living of patients with inclusion body myositis

Therapeutic indications : Myositis, Inclusion Body

default distrib

IBS-D / Irritable Bowel Syndrome - Diarrhea Irritable Bowel Syndrome - Diarrhea

Astellas Pharma Europe Ltd et al.

To evaluate treatment benefit in diarrhea-predominant IBS (IBS-D)

Therapeutic indications : Irritable Bowel Syndrome

default distrib

IBS-QOL / Irritable Bowel Syndrome - Quality Of Life Irritable Bowel Syndrome - Quality Of Life

Patrick DL, Drossman DA, Novartis Pharmaceuticals Corporation et al.

To assess the impact of Irritable Bowel Syndrome and its treatment

Therapeutic indications : Irritable Bowel Syndrome

default distrib

IBS-SSS / Irritable Bowel Syndrome Severity Scoring System Irritable Bowel Syndrome Severity Scoring System

Francis CY, Morris J, Whorwell PJ et al.

To assess and investigate Irritable Bowel Syndrome

Therapeutic indications : Irritable Bowel Syndrome

default distrib

IBSQoL / Irritable Bowel Syndrome Quality of Life Questionnaire Irritable Bowel Syndrome Quality of Life Questionnaire

GlaxoSmithKline Research and Development Limited (GSK) et al.

To measure the impact of irritable bowel syndrome (IBS) on dimensions of quality of life

Therapeutic indications : Irritable Bowel Syndrome

default distrib

ICDSQ© / Impact of Celiac Disease Symptoms Questionnaire© Impact of Celiac Disease Symptoms Questionnaire©

Alvine therapeutics et al.

To assess the negative impact of celiac disease symptoms

Therapeutic indications : Celiac Disease

default distrib

ICQ and ICQ-S / Inhaled Corticosteroid Questionnaire Inhaled Corticosteroid Questionnaire

van der Molen T, Foster JM et al.

To measure patients' inhaled corticosteroids (ICS) related side effect perceptions

Therapeutic indications : Asthma, Pulmonary Disease, Chronic Obstructive

default distrib

IDS-SR and IDS-C / Inventory of Depressive Symptomatology Inventory of Depressive Symptomatology

Rush AJ et al.

To assess depressive symptom severity [ These assessments can be used to screen for depression, although they have been used predominantly as measures of symptom severity ]

Therapeutic indications : Depression

default distrib

IEQ / Injustice Experience Questionnaire Injustice Experience Questionnaire

Sullivan MJ, Adams H, Horan S, Maher D, Boland D, Gross R et al.

To assess perceive injustice associated with injury

Therapeutic indications : Injuries, Musculoskeletal Pain

default distrib

IEQ-SF / Injustice Experience Questionnaire - Short Form Injustice Experience Questionnaire - Short Form

Sullivan MJ, Adams H, Horan S, Maher D, Boland D, Gross R et al.

To assess perceptions of injustice associated with the experience of debilitating health and mental health conditions

Therapeutic indications : Chronic Diseases, Musculoskeletal Pain, Depressive Disorder, Major

default distrib

IGA/PGA Scale / Investigator’s Global Assessment (or Physician's Global Assessment) Scale Investigator’s Global Assessment (or Physician's Global Assessment) Scale

Rao DB, Georgiev EL, Paul PD, Guzman AB et al.

To evaluate the overall severity of atopic dermatitis

Therapeutic indications : Dermatitis, Atopic

default distrib

IGFDQ© / Impact of a Gluten-Free Diet Questionnaire Impact of a Gluten-Free Diet Questionnaire

Alvine therapeutics et al.

To assess the negative impact of managing a gluten-free diet

Therapeutic indications : Celiac Disease

default distrib

IHSS / Idiopathic Hypersomnia Severity Scale Idiopathic Hypersomnia Severity Scale

Dauvilliers Y et al.

To evaluate the severity and consequences of symptoms in patients with idiopathic hypersomnia.

Therapeutic indications : Narcolepsy

default distrib

IIQ / Incontinence Impact Questionnaire Incontinence Impact Questionnaire

Shumaker SA, Fantl JA, Wyman JF, Uebersax JS, McClish D et al.

To measure the impact of urinary incontinence on activities, roles, and emotional states in women

Therapeutic indications : Urinary Incontinence

default distrib

INQoL / Individualized Neuromuscular Quality of Life Questionnaire Individualized Neuromuscular Quality of Life Questionnaire

Carr AJ, Rose MR, Vincent KA et al.

To assess health-related quality of life of patient suffering from neuromuscular diseases.

Therapeutic indications : Muscular Diseases, Myasthenia Gravis

default distrib

IRLS / International Restless Legs Syndrome Study Group Rating Scale International Restless Legs Syndrome Study Group Rating Scale

Allen RP, Walters AS et al.

To measure the severity of Restless Legs Syndrome (RLS)

Therapeutic indications : Restless Legs Syndrome

default distrib

ISI / Insomnia Severity Index Insomnia Severity Index

Morin CM et al.

To quantify the patient's perception of insomnia severity, and its impact on daytime functioning

Therapeutic indications : Sleep Disorders (includes apnea)